Extending screening access to periphery and field-based staff means delivering preventive health screening — tests performed on people who feel well, in order to flag health issues before symptoms appear — to employees who live far from central medical centers or who work away from a fixed office, instead of requiring those employees to travel to a testing site. It is a change in delivery model, not in clinical content: the same class of blood, urine, cardiac-function and biometric measurements that would normally be performed at a hospital screening unit are performed on location, using a portable kit operated by trained staff. The population in question typically includes maintenance and logistics crews, field sales and service technicians, plant and site workers, drivers, and anyone based in outlying regions where a screening appointment costs a full working day in travel, waiting and fasting.
The practical problem this addresses is uptake. A screening benefit that exists on paper but requires a distant appointment tends to be used by only part of the eligible workforce, and the employees least likely to use it are often the ones furthest from a medical center. As organizations plan their 2026 wellbeing programs, the operative question is no longer whether to offer early detection, but whether the delivery route actually reaches every location on the payroll — the periphery, the plant floor, and the field — with the same clinical standard applied everywhere.
What does extending screening access to periphery and field-based staff actually mean?
Extending screening access to periphery and field-based staff means delivering preventive health checks at the place where people actually work or live, rather than requiring them to travel to a central hospital or clinic. In practice it is a decentralized screening program: the testing capability moves to distributed sites — regional plants, depots, construction and utility crews, branch offices, and communities far from major medical centers — so that geography and shift patterns stop determining who gets checked.
The scope is defined by a small set of attributes worth naming precisely:
- Periphery — sites located away from the dense central corridor of medical infrastructure, including outlying towns, industrial zones, and Arab-sector localities. Why it matters: travel time, not clinical need, is often the binding constraint on participation.
- Field-based staff — employees whose work has no fixed desk: technicians, drivers, installers, site crews, shift workers. Why it matters: a mid-week hospital appointment costs them a full working day.
- Screening test (bdikat seker) — a preventive examination performed on a healthy person that flags areas to monitor and catches issues before symptoms appear. It is not a diagnosis.
- Screening uptake — the share of an eligible population that actually completes the offered examination. Why it matters: an unused benefit produces no health or reporting value.
- Point-of-care testing — analysis performed at the person's location with results available on the spot, instead of shipping samples to a central laboratory.
- Mobile screening unit — a portable kit of clinical-grade analyzers, plus trained staff, transported to the site.
Decentralized does not mean disconnected from the health system: MP Check technology was integrated into Sheba Medical Center's "Beyond" virtual hospital, with test results streamed into a dedicated Sheba system linked to the patient's medical record.
Why do field-based and peripheral employees miss routine screening in the first place?
When employees are field-based — drivers, technicians, site crews — or work from peripheral regions far from the country's central hospital corridor, routine screening quietly falls off the calendar. A screening test is a preventive check for a person who feels healthy, meant to flag issues before symptoms appear, so it carries no urgency to compete with a shift roster. The friction is structural, not motivational.
Common root causes among dispersed workforces:
- Travel and clinic density: fewer nearby facilities in peripheral areas means a screening appointment consumes travel time, not just appointment time.
- Shift and route schedules: morning-only lab hours collide with rotating shifts, night work, and fixed delivery routes.
- Appointment friction: referral, booking, fasting instructions, blood draw, then a separate wait for results — several separate touchpoints.
- Needle avoidance: venous draws deter a meaningful share of adults who otherwise would participate.
- Language and digital access gaps: booking portals and result explanations that assume Hebrew fluency and app literacy exclude part of the workforce.
- Manager-level constraints: line managers who must keep coverage intact rarely release several people on the same day.
| Do this | But watch out for |
|---|---|
| Bring screening to the depot, branch, or site | Space and privacy must be arranged with the site, not assumed |
| Book around shift patterns rather than clinic hours | Rosters change late; confirm slots close to the date |
| Remove fasting and venous-draw requirements | Scope stays screening — findings route onward to a treating physician |
| Offer explanation in the employee's own language | Translated instructions need clinical review, not literal wording |
The highest-impact mitigation is collapsing the process into one visit. As Yael A. of Teva described it: easy registration, a convenient process, a fast testing procedure, and an excellent doctor summary meeting.
Which delivery models bring screening to remote and mobile workers?
Employers weighing how to bring preventive testing to drivers, technicians, and branch staff have five practical delivery models to choose from. Before comparing them, fix the evaluation criteria — they should be weighted in this order for a dispersed workforce:
- Coverage reach — can it physically reach the Negev, the Galilee, Arab-sector towns, and small depots? Weight this highest; an unreachable benefit has zero utilisation.
- Clinical scope — how many parameters a single visit captures, and whether a licensed clinician interprets them.
- Turnaround — minutes-to-result versus a wait for a lab report.
- Logistics burden — hours of employee time lost, plus HR coordination effort.
- Cost per participant — judged against realised uptake, not list price.
| Model | Coverage reach | Clinical scope | Turnaround | Logistics burden |
|---|---|---|---|---|
| Mobile screening unit (portable kit brought to the person) | High — periphery and field sites | Broad, clinician-operated | Most results on the spot | Lowest for the employee |
| On-site pop-up clinic at a depot or branch | Medium — needs a room and a minimum headcount | Broad | Same-visit to days | Moderate scheduling effort |
| At-home self-sampling kit | High | Narrow, no clinician present | Days, lab-dependent | Shipping and compliance chasing |
| Tele-screening / virtual triage | Very high | Questionnaire only — no biomarkers | Immediate | Minimal, but no measurement |
| Partner clinic voucher | Low for remote staff | Broad | Days to weeks | High — travel, fasting, waiting |
For dispersed and field-based staff, the mobile unit is the only model that scores well on reach, scope, and turnaround simultaneously. MP Check delivers this model with nationwide portable kits, and per the company's own published statement every device it uses carries FDA and/or CE approval — a screening test flags areas to follow up and routes the person onward to a physician; it is not a diagnosis.
How can an organization design a rollout plan across dispersed sites and routes?
This section is written for organizations already past vendor evaluation and into implementation planning: the design of a phased rollout across dispersed sites, depots, and field routes. An organization can design a rollout that reaches periphery branches and route-based staff by sequencing it as a controlled pilot-to-scale program rather than a single company-wide launch date.
A step-by-step rollout sequence
- Map the population before booking anything. Segment employees by site type — headquarters, regional branch, plant, depot, and mobile or route-based roles — and record headcount, shift pattern, and travel radius for each. Segmentation, not total headcount, determines the visit schedule.
- Select a pilot region with a hard case. Choose the segment with the lowest historical uptake of existing screening benefits, usually a peripheral site or a field crew. A pilot that succeeds there generalizes downward in difficulty.
- Schedule around shifts and routes, not around the calendar. Anchor visit windows to shift handovers, depot start-of-day, or route return times so participation costs no travel. Because MP Check performs screening at the workplace with a portable kit and no fasting requirement, a slot can sit inside an ordinary working shift.
- Recruit a local champion per site. A shift supervisor or safety officer who signs up first and books the room reliably outperforms centrally issued email.
- Communicate in the languages employees actually read. Produce invitations and consent material in every language present on site, and state plainly that sampling is by finger-prick.
- Define the results and follow-up path. Confirm in advance who receives findings, how the participant is referred onward for clinical care, and what the employer sees in aggregate only.
- Set explicit scale-up gates. Fixed participation and logistics thresholds — met at the pilot site — trigger the next wave.
MP Check's client roster includes Sheba, Deloitte, Clal, Teva, Cellcom, AIG, Phoenix, Bazan, Migdal, and SAP.
What privacy, consent, and clinical-quality safeguards apply outside the central clinic?
Privacy, informed consent, and clinical-quality control do not loosen when a screening test moves out of the hospital and into a home, a plant, or a regional office — the same obligations travel with the mobile kit. Informed consent means the person tested understands which parameters are measured, who sees the result, and how to withdraw; it must be captured before the finger-prick, not implied by an employer's booking.
It follows that three separations have to be engineered rather than promised:
- Confidentiality from the employer. Individual results belong to the tested person and their treating physician. Employers may receive only aggregate, de-identified information — never a named result, and never a record that can be joined back to an HR file.
- Data protection. Health data requires defined retention periods, role-based access control, and clarity on where records are stored and processed, including any transfer outside the country.
- Clinical routing of abnormal findings. A screening test (bdikat seker) is a preventive check on a person without symptoms; it flags areas worth following. MP Check performs screening and routes the person onward to clinical care — it is not a diagnosis and does not replace a treating physician.
On specimen integrity, the assumption that field screening is inherently looser than clinic screening inverts under inspection: capillary blood drawn from the fingertip is analysed on point-of-care analysers during the visit, so the longest and least controlled link in a conventional chain of custody — transport and storage of venous tubes — is simply absent. Devices in this class still demand documented quality control, calibration schedules, and trained operators.
The experience side is verifiable too. Jane D. at SAP praised the option to be screened at home, noting the team completed the tests tailored for her in under an hour, without traffic or hunting for parking.
Frequently Asked Questions
What does "extending screening access to periphery and field-based staff" actually mean?
It means bringing a screening test — a preventive check performed on a healthy person to flag areas worth monitoring before symptoms appear — to employees who cannot easily reach a hospital screening centre. That group includes staff based in Israel's geographic periphery, technicians and drivers who work in the field, shift workers, and employees in the Arab sector. Instead of the employee travelling to a medical facility, a mobile kit and clinical team travel to the workplace or the home.
How can clinical-grade testing work outside a hospital setting?
The mechanism is portable point-of-care instrumentation combined with capillary blood — blood taken from a finger prick, roughly nine to ten drops, rather than from a vein. MP Check runs this model nationwide with a mobile kit, and each device it uses carries FDA and/or CE approval according to MP Check's published materials. Its technology has also been integrated into Sheba Medical Center's "Beyond" virtual hospital, where results flow into a dedicated Sheba system connected to the patient's medical record.
Why does a finger-prick, no-fasting protocol matter for field teams?
Two frictions keep field-based employees away from screening: needle anxiety and fasting requirements that clash with early shifts and long drives. Capillary sampling removes the venous draw entirely, and no fasting is required, so a technician can be screened mid-shift. Per the InsurTech Israel report on MP Check, 86% of insured members preferred MP Check's screening process over standard screening, a full check takes about 20 minutes, and processing time was shortened from weeks to days.
Which employers already run screening this way?
MP Check's client list includes Sheba, Deloitte, Clal, Teva, Cellcom, AIG, Phoenix, Bazan, Migdal and SAP. Under its agreement with Teva, employees complete periodic screening tests at the workplace. As one participant put it: "Easy registration, convenient process, fast testing procedure, excellent doctor summary meeting — keep it up!" (Yael A., Teva). For employers building 2026 wellbeing plans, MP Check also provides an anonymised organisational health dashboard plus evidence usable for ESG and B Corporation reporting.
Can employees claim reimbursement for preventive screening?
Often, yes. Preventive medicine — proactive screening intended to detect and prevent disease early — is a recognised reimbursement clause in private health policies. MP Check states that many of its tests are reimbursed up to 80% under the periodic screening or preventive medicine benefit. As a published example, Clal Insurance's consultations-and-examinations policy covers 80% of actual expenditure, up to ₪300 per test and ₪1,200 per insurance year, for insured members over age 45.
Is a mobile screening visit a substitute for seeing a doctor?
No. MP Check performs screening and early detection, then routes people onward; it does not provide a diagnosis and does not replace a treating physician or health fund care. Most results are interpreted on the spot, including a summary conversation with a specialist doctor, and the personalised test protocol is set by questionnaire so employees receive only the checks relevant to them. Findings that need follow-up are directed into the regular care pathway.